Our Purpose
To target the biology that makes cancer aggressive.
A radiopharmaceutical company built around targeting uPAR and aggressive cancer biology
Curasight is developing uPAR-targeted radiopharmaceuticals with the aim of turning a human-characterized marker of aggressive cancer biology into a new class of radioligand therapy.
Curasight was founded in Denmark to translate research from Rigshospitalet and the University of Copenhagen into medicines and imaging agents for patients with cancer. The company is listed on Spotlight Stock Market under ticker CURAS.
The company combines a single uPAR target strategy with two platform brands.
uTRACE® covers imaging and diagnostic development, while uTREAT® covers therapeutic development. Within those platforms sit individual uPAR-targeting ligands and distinct radionuclide-specific product candidates, including the current glioblastoma development program and the next-generation ligands designed for modular alpha and beta payloads for additional solid tumor types.
Imaging and diagnostic development
uTRACE®
Therapeutic development
uTREAT®
Our Purpose
Many radioligand therapies
A particular tissue or tumor lineage
Many radioligand therapies are built around targets associated with a particular tissue or tumor lineage.
Curasight
The invasive and metastatic phenotype
Curasight is pursuing a different biological idea: target uPAR, a receptor associated with the invasive and metastatic phenotype across multiple solid tumors.
Our purpose is to develop radiopharmaceuticals that can identify patients whose tumors express uPAR and, where therapeutic radioligand therapy (RLT) development is successful, deliver radiation to those tumors with precision.
This biology-led approach is designed to support development across selected aggressive cancers while using imaging and dosimetry to inform patient selection and treatment planning.
